Navigation Links
Questcor Reports Fourth Quarter and Full Year 2012 Results
Date:2/26/2013

zed remaining under the stock repurchase plan. Shares outstanding were 58.5 million at December 31, 2012 and 63.6 million at December 31, 2011.

The company today announced that its Board of Directors has declared a quarterly cash dividend of $0.25 per share to all shareholders of record at the close of business on April 22, 2013. The quarterly cash dividend was increased from $0.20 per share, or 25% over the previous quarterly dividend. The dividend is scheduled to be paid on or about April 30, 2013. Questcor currently intends to pay regular quarterly cash dividends for the foreseeable future.

2012 Corporate Highlights

  • During 2012, approximately 7,000 patients received new prescriptions for Acthar.
  • During 2012, additional academic papers were published providing incremental information regarding Acthar and its potential immuno-modulating properties and mechanisms of action.
  • During 2012, Questcor initiated two multi-center clinical trials, continued enrollment in a third, and initiated discussions with the FDA for a fourth trial.
  • During the second quarter of 2012, the company completed the expansion of its Nephrology sales force to 58 from 28 representatives.
  • In the third quarter of 2012, the company completed the expansion of its neurology sales force to 107 from 77 representatives.
  • In the third quarter of 2012, Questcor initiated commercial efforts for Acthar in the treatment of rheumatology-related indications already included on the FDA-approved package insert for Acthar. Acthar is indicated for multiple FDA-approved rheumatology-related conditions, including its use as adjunctive therapy in psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing spondylitis. Acthar is also approved by the FDA as acute or maintenance therapy in selected cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).
  • In the four
    '/>"/>

  • SOURCE Questcor Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
    2. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
    3. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
    4. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
    5. Questcor to Conduct Conference Call to Discuss Reimbursement Process
    6. Questcor Comments on Insurance Policy Bulletin
    7. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
    8. Questcor Pharmaceuticals to Present at Investor Conferences in September
    9. Questcor Reports Second Quarter Financial Results
    10. Questcor to Report Second Quarter Results on July 24, 2012
    11. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/7/2015)... SHENZHEN, China , July 7, 2015 /PRNewswire/ -- ... ), a leading developer, manufacturer and marketer of ... to acquire the remaining stake in Wuhan Dragonbio ... million. Dragonbio is a domestic ... joint and other surgical products. Prior to today,s ...
    (Date:7/7/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... technology to treat obesity, metabolic diseases, and other gastrointestinal ... offering of 32,000,000 units. Each unit consists of one share ... purchase one share of common stock at a purchase ... units in the offering would result in them beneficially ...
    (Date:7/7/2015)... July 7, 2015 Oasmia ... of drugs within human and veterinary oncology, today ... in the United States , ... leading companion animal therapeutic.      (Logo: ... ) , Paccal Vet-CA1 was ...
    Breaking Medicine Technology:Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3Oasmia Pharmaceutical Launches US Brand and Sales Platform 2
    ... NASHVILLE, Tenn., Aug. 4, 2011 Cumberland Pharmaceuticals Inc ... focused on hospital acute care and gastroenterology markets, today announced ...   For the three months ended June 30, 2011, net ... the prior year period. The growth in revenue was due ...
    ... Calif., Aug. 4, 2011 DURECT Corporation (Nasdaq: ... ended June 30, 2011. Total revenues increased to $7.8 million ... million for the three months ended June 30, 2010.  Net ... $5.2 million, compared to a net loss of $6.3 million ...
    Cached Medicine Technology:Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 2Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 3Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 4Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 5Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 6Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 7Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 8Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 9Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 10Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 11Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results 12DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs 8
    (Date:7/7/2015)... ... ... Quadrino Law Group is pleased to announce the relocation of the firm's ... new facility is a state of the art building, located with easy access to ... and founder, said, "We are pleased to service our clients from such a premier ...
    (Date:7/7/2015)... ... July 07, 2015 , ... ... global provider of advanced delivery technologies and development solutions for drugs, biologics ... licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) ...
    (Date:7/7/2015)... ... , ... Summer is a great time to get outside and be active. ... safety tips. , Jean Tapley, senior wellness coordinator at Amica, suggests the following seven ... Start slowly. Going from no activity to several hours of activity can potentially ...
    (Date:7/7/2015)... ... July 07, 2015 , ... On Saturday, May 16th, 2015, the ... Manistee Golf and Country Club. Best Drug Rehabilitation staff members were delighted to join ... underprivileged children. Kiwanis International, the parent of the Manistee Kiwanis Club, is a global ...
    (Date:7/7/2015)... ... July 07, 2015 , ... FSAstore.com today announced the launch ... holders. HSAstore.com makes it simple to use, spend and manage HSA funds with innovative ... accounts. , According to a report by Devenir , approximately 13.8 million ...
    Breaking Medicine News(10 mins):Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 3
    ... A chronic shortage of health workers in developing nations ... tuberculosis and malaria// , World Health Organization Director-General Margaret ... Health Day on April 7. ,Thousands of ... nations in search of higher paying jobs in wealthier ...
    ... and very poor, has banned the life-threatening practice of female ... ,Anybody involved in female genital mutilation (FGM) would be punished ... ,The move follows a campaign against the practice by the ... of Eritrean women are circumcised. ,'Female circumcision ...
    ... uncomfortable symptoms and help women feel better while going through ... in a woman's life when her menstrual cycle, associated with ... age 45. ,The four-month study by Penn ... 160 women, dividing them into three groups. ,One ...
    ... V’s Rabies monoclonal antibody (mAb) product has entered a ... launching// a similar study in the US. ... for the post-exposure prophylaxis of rabies, using Crucell’s MAbstract ... is closely linked to the initial phase I study ...
    ... Pharmaceuticals has treated the first patient in a new ... of Ceflatonin// (homoharringtonine or HHT) in patients with Chronic ... to treatment with two or more prior tyrosine kinase ... to complement the ongoing registration-directed clinical trial in CML ...
    ... New York City’s Department of Health and Mental Hygiene is ... AIDS to get circumcised in light of the World Health ... prevent the disease. ,In the United States, “New York ... R. Frieden, the city’s health commissioner, said in an interview. ...
    Cached Medicine News:Health News:Eritrea Bans Female Circumcision 2Health News:Crucell's Rabies MAb Enters Phase I Trial in India 2Health News:New York City Plans to Promote Circumcision 2
    ... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
    ... powder reagent once reconstituted offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
    LCD chart display...
    Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
    Medicine Products: